Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas - Takeaways - MDSpire

Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas

  • By

  • Julia A. Yescas

  • Christopher G. Bunick

  • Ayman Grada

  • Joan Guitart

  • Carlos A. Torres-Cabala

  • I. Caroline Le Poole

  • Xiaolong A. Zhou

  • May 13, 2026

Share

  • 1

    Cutaneous T-cell lymphomas (CTCLs) are aggressive skin-homing T-cell malignancies with limited curative treatment options.

  • 2

    Genomic studies reveal recurrent alterations in tyrosine kinase pathways in aggressive CTCL subtypes, particularly PCAETL and PCGDTL.

  • 3

    Tyrosine kinase inhibitors (TKIs) like ruxolitinib and pemigatinib show potential but often lead to transient responses and acquired resistance.

  • 4

    Resistance mechanisms include secondary kinase domain mutations and adverse events that hinder ongoing treatment efficacy.

  • 5

    Durable responses in CTCL may require molecular stratification, genomic monitoring, and combination therapy strategies.

Original Source(s)

Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas

  • by Julia A. Yescas, Christopher G. Bunick, Ayman Grada, Joan Guitart, Carlos A. Torres-Cabala, I. Caroline Le Poole, Xiaolong A. Zhou

  • May 13, 2026

Related Content

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants

Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American...

Unique Phase I NSCLC Trial Sites Decreasing in United States

The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant conso...